ME02433B - Nitrooksiderivati prostaglandina - Google Patents

Nitrooksiderivati prostaglandina

Info

Publication number
ME02433B
ME02433B MEP-2016-79A MEP7916A ME02433B ME 02433 B ME02433 B ME 02433B ME P7916 A MEP7916 A ME P7916A ME 02433 B ME02433 B ME 02433B
Authority
ME
Montenegro
Prior art keywords
disease
compound
cerebral
anxiety disorder
diseases
Prior art date
Application number
MEP-2016-79A
Other languages
English (en)
French (fr)
Inventor
Ennio Ongini
Francesca Benedini
Valerio Chiroli
Soldato Piero Del
Original Assignee
Nicox Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34778199&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02433(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nicox Sa filed Critical Nicox Sa
Publication of ME02433B publication Critical patent/ME02433B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0016—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing only hydroxy, etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Predmetni pronalazak se odnosi na jedinjenje sa skeletom azola koje ima antagonistielo dejstvo prema arginin-vazopresinskom (AVP) receptoru Vlb, kao i na Predmetni pronalazak se odnosi na jedinjenje sa skeletom azola koje ima antagonistielo  dejstvo prema arginin-vazopresinskom (AVP) receptoru Vlb, kao i na farmaceutske preparate koji sadde navedeno jedinjenje kao aktivni sastojak, posebno nasredstva za leenje ili prevenciju bolesti kao gto su poreme6aji raspololenja (uldjueujueidepresiju), anksiozni poremedaj, S'izofrenija, Alchajmerova bolest, Parkinsonova bolest,Hantingtonova horeja, poremeeaj ishrane, hipertenzija, gastrointestinalna bolest, zavisnost odnarkotika, epilepsija, cerebralni infarkt, cerebralna ishemija, cerebralni edem, povreda glave,zapaljenje, bolesti u vezi sa imunim sistemom i alopecija. farmaceutske preparate koji sadde navedeno jedinjenje kao aktivni sastojak, posebno na sredstva za leenje ili prevenciju bolesti kao gto su poreme6aji raspololenja (uldjueujuei depresiju), anksiozni poremedaj, S'izofrenija, Alchajmerova bolest, Parkinsonova bolest, Hantingtonova horeja, poremeeaj ishrane, hipertenzija, gastrointestinalna bolest, zavisnost od narkotika, epilepsija, cerebralni infarkt, cerebralna ishemija, cerebralni edem, povreda glave, zapaljenje, bolesti u vezi sa imunim sistemom i alopecija.
MEP-2016-79A 2004-01-05 2004-12-27 Nitrooksiderivati prostaglandina ME02433B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04100001 2004-01-05
EP04804405.1A EP1704141B1 (en) 2004-01-05 2004-12-27 Prostaglandin nitrooxyderivatives
PCT/EP2004/014820 WO2005068421A1 (en) 2004-01-05 2004-12-27 Prostaglandin nitrooxyderivatives

Publications (1)

Publication Number Publication Date
ME02433B true ME02433B (me) 2016-09-20

Family

ID=34778199

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2016-79A ME02433B (me) 2004-01-05 2004-12-27 Nitrooksiderivati prostaglandina

Country Status (40)

Country Link
US (5) US7273946B2 (me)
EP (3) EP3002277B1 (me)
JP (1) JP3984283B2 (me)
KR (2) KR100854838B1 (me)
CN (1) CN100469765C (me)
AP (1) AP2006003638A0 (me)
AR (2) AR047081A1 (me)
AU (1) AU2004313688B2 (me)
BR (1) BRPI0418245B8 (me)
CA (1) CA2551409C (me)
CR (2) CR8498A (me)
CY (1) CY1117417T1 (me)
DK (1) DK1704141T3 (me)
EA (1) EA010595B1 (me)
EC (1) ECSP066684A (me)
ES (2) ES2767136T3 (me)
GE (1) GEP20094780B (me)
GT (1) GT200500293A (me)
HK (1) HK1096084A1 (me)
HR (1) HRP20160500T1 (me)
HU (1) HUE027357T2 (me)
IL (1) IL176416A (me)
MA (1) MA28284A1 (me)
ME (1) ME02433B (me)
MX (1) MXPA06007678A (me)
MY (1) MY147181A (me)
NO (2) NO337217B1 (me)
NZ (1) NZ548271A (me)
OA (1) OA13356A (me)
PA (1) PA8620901A1 (me)
PE (1) PE20051052A1 (me)
PL (1) PL1704141T3 (me)
RS (1) RS54717B1 (me)
SI (1) SI1704141T1 (me)
TN (1) TNSN06210A1 (me)
TW (1) TWI337994B (me)
UA (1) UA84726C2 (me)
UY (1) UY28709A1 (me)
WO (1) WO2005068421A1 (me)
ZA (1) ZA200605354B (me)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02433B (me) 2004-01-05 2016-09-20 Nicox Sa Nitrooksiderivati prostaglandina
JP2009500315A (ja) * 2005-06-29 2009-01-08 ファイザー・インク フルオロプロスタグランジンのニトロ誘導体
CA2613748A1 (en) * 2005-06-29 2007-01-04 Pfizer Inc. Prostaglandin derivatives
EP2007705A4 (en) * 2006-03-29 2011-09-07 Nicox Sa NITROGEN MONOXIDE REINFORCING PROSTAGLANDIN COMPOUNDS, COMPOSITION AND APPLICATION PROCESS
US20090238763A1 (en) 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
US20090221703A1 (en) 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
DE102006052755A1 (de) * 2006-11-08 2008-05-15 N-Zyme Biotec Gmbh Michaelsysteme als Transglutaminaseinhibitoren
JP2010513262A (ja) 2006-12-15 2010-04-30 ニコックス エス エイ カルボニックアンヒドラーゼ阻害剤誘導体
WO2008071421A1 (en) * 2006-12-15 2008-06-19 Nicox S.A. Nitrate esters of carbonic anhydrase inhibitors
KR101853971B1 (ko) 2007-06-04 2018-05-02 테크필즈 인크 매우 높은 피부 및 막 침투율을 가지는 비스테로이드성 소염제(ｎｓａｉａ) 약물전구체 및 이들의 새로운 의약적 용도
WO2009035565A1 (en) * 2007-09-07 2009-03-19 Qlt Plug Delivery, Inc Prostaglandin analogues for implant devices and methods
US7632868B2 (en) * 2007-10-31 2009-12-15 Meta Cosmetics, Llc Prostaglandin analog compositions to treat epithelial-related conditions
AR076731A1 (es) * 2008-05-09 2011-07-06 Pfizer Prostamidas donadoras de oxido nitrico, uso de los mismos y composiciones farmaceuticas
US7807716B2 (en) * 2008-09-24 2010-10-05 Oral Delivery Technology Ltd. Nitric oxide amino acid ester compound, compositions for increasing nitric oxide levels and method of use
BRPI0922263B1 (pt) 2008-12-04 2021-08-31 Chongxi Yu Composição de alta penetração de um fármaco principal, e seus usos
US8637558B2 (en) 2008-12-30 2014-01-28 Industry-Academic Cooperation Foundation, Chosun University Thiazolidinedione derivative and use thereof
CN102498088A (zh) * 2009-09-15 2012-06-13 帝斯曼知识产权资产管理有限公司 硝基氧基酯及其制备和用途
CN101885684B (zh) * 2010-07-01 2013-10-30 南京中医药大学 带有一氧化氮供体的芳香酸前体药物及其制备方法和其应用
EP3290024B1 (en) 2011-08-29 2019-04-17 Mati Therapeutics Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension
HU231203B1 (hu) * 2011-12-21 2021-10-28 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Új eljárás travoprost előállítására
JP6213560B2 (ja) 2012-05-03 2017-10-18 マティ セラピューティクス，インク． 薬剤送達システムならびに開放隅角緑内障および高眼圧症を治療する方法
CN104994845B (zh) * 2012-10-23 2017-11-17 尼科斯科学爱尔兰公司 用于眼科应用的醌基一氧化氮供体化合物
ES2624446T3 (es) * 2013-04-18 2017-07-14 Nicox Science Ireland Compuestos donantes de óxido nítrico a base de quinona para uso oftalmológico
US9913849B2 (en) 2014-01-10 2018-03-13 Manistee Partners Llc Treatment of migraines
CN107106573A (zh) * 2014-10-15 2017-08-29 诺华股份有限公司 用于治疗青光眼和眼压过高的前列腺素偶联物和衍生物
US10047047B2 (en) 2015-03-31 2018-08-14 Nicox S.A. Nitric oxide donating derivatives of latanoprost free acid
WO2016155906A1 (en) * 2015-03-31 2016-10-06 Nicox S.A. Nitric oxide donating derivatives of fluprostenol
EP3088388A1 (en) 2015-04-30 2016-11-02 NicOx S.A. Nitric oxide donating derivatives of prostaglandins
CA2999766A1 (en) 2015-09-22 2017-03-30 Graybug Vision, Inc. Compounds and compositions for the treatment of ocular disorders
HU231175B1 (hu) * 2015-12-04 2021-06-28 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Tetszőleges, előre meghatározott minőségű Latanoprostene bunod előállítása gravitációs kromatográfiával
CA3043000A1 (en) 2016-11-08 2018-05-17 Bausch & Lomb Incorporated Nitric oxide releasing prostaglandin derivatives for treating normal tension glaucoma
KR102069205B1 (ko) 2017-08-09 2020-01-22 연성정밀화학(주) 라타노프로스틴 부노드의 제조 방법 및 그를 위한 중간체
RU2718744C2 (ru) 2018-05-17 2020-04-14 Общество с ограниченной ответственностью "Гурус БиоФарм" Производные простагландина F2альфа для снижения внутриглазного давления
CN109988089B (zh) * 2018-05-29 2022-04-26 上海凡秦医药科技有限公司 一种前列腺素化合物、制备方法及其用途
CN108892624B (zh) * 2018-06-20 2020-12-15 重庆威鹏药业有限公司 沙库巴曲硝基氧衍生物及其制备方法和应用
US11332433B2 (en) * 2020-07-24 2022-05-17 Chirogate International Inc. Process for the preparation of latanoprostene bunod and intermediate thereof and compositions comprising the same
CN113943266A (zh) * 2021-11-18 2022-01-18 广州楷石医药有限公司 一种氧化氮供体型贝前列素类衍生物及其药物组合物和用途
CN116444377A (zh) * 2022-01-07 2023-07-18 广州楷石医药有限公司 一种氧化氮供体型曲前列尼尔类衍生物及其药物组合物和用途
CA3195291A1 (en) * 2022-04-13 2023-10-13 Caravel Therapeutics, Inc. Preservative-free ophthalmic pharmaceutical emulsion and its application

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3922293A (en) 1971-12-30 1975-11-25 Upjohn Co Prostaglandin F-type 9-monoacylates
US4952581A (en) 1987-04-03 1990-08-28 The Trustees Of Columbia University In The City Of New York Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
EP0569046B1 (en) 1988-09-06 2002-11-13 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
AU674038B2 (en) 1992-10-13 1996-12-05 Alcon Laboratories, Inc. Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma
US5328933A (en) * 1992-10-28 1994-07-12 Allergan, Inc. Cyclopentane heptenylnitro and heptanylnitro-2-aliphatic or aryl aliphatic derivatives and homologues
US5625083A (en) * 1995-06-02 1997-04-29 Bezuglov; Vladimir V. Dinitroglycerol esters of unsaturated fatty acids and prostaglandins
IT1295694B1 (it) 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
IT1292377B1 (it) * 1997-06-19 1999-02-08 Nicox Sa Composizioni farmaceutiche a base di prostaglandine
US6417228B1 (en) 1998-11-02 2002-07-09 Alcon Manufacturing, Ltd.. 13-Aza prostaglandins for the treatment of glaucoma and ocular hypertension
AU3713600A (en) 1999-03-01 2000-09-21 Nitromed, Inc. Nitrosated and nitrosylated prostaglandins, compositions and metods of use
AR035541A1 (es) 2000-11-13 2004-06-16 Pharmacia Ab Un metodo de tratamiento para pacientes que sufren de glaucoma severo o necesitan una reduccion de la presion intraocular (pio) y el uso de una combinacion de agentes reductores de la pio
US7816399B2 (en) * 2001-04-19 2010-10-19 Teika Pharmaceutical Co., Ltd. Medicines and medicinal kits
ME02433B (me) * 2004-01-05 2016-09-20 Nicox Sa Nitrooksiderivati prostaglandina

Also Published As

Publication number Publication date
PE20051052A1 (es) 2005-12-17
US7910767B2 (en) 2011-03-22
MY147181A (en) 2012-11-14
EA010595B1 (ru) 2008-10-30
WO2005068421A1 (en) 2005-07-28
KR20060113753A (ko) 2006-11-02
UA84726C2 (ru) 2008-11-25
HRP20160500T1 (hr) 2016-06-03
PL1704141T3 (pl) 2016-08-31
TW200526567A (en) 2005-08-16
US7629345B2 (en) 2009-12-08
MA28284A1 (fr) 2006-11-01
MXPA06007678A (es) 2006-09-01
NO20151341A1 (no) 2006-09-07
AU2004313688B2 (en) 2010-08-05
EP1704141B1 (en) 2016-02-24
US20080058392A1 (en) 2008-03-06
DK1704141T3 (en) 2016-05-02
US20050272743A1 (en) 2005-12-08
JP2007518716A (ja) 2007-07-12
PA8620901A1 (es) 2005-08-30
HK1096084A1 (en) 2007-05-25
US8058467B2 (en) 2011-11-15
TNSN06210A1 (fr) 2007-12-03
CN1906159A (zh) 2007-01-31
ES2566800T3 (es) 2016-04-15
EP3643702A1 (en) 2020-04-29
ZA200605354B (en) 2009-09-30
SI1704141T1 (sl) 2016-04-29
NO337217B1 (no) 2016-02-15
AP2006003638A0 (en) 2006-06-30
US7273946B2 (en) 2007-09-25
CY1117417T1 (el) 2017-04-26
EA200601099A1 (ru) 2006-10-27
NO339685B1 (no) 2017-01-23
US20110136904A1 (en) 2011-06-09
BRPI0418245B1 (pt) 2017-05-30
RS54717B1 (en) 2016-08-31
CR20110131A (es) 2011-03-30
ECSP066684A (es) 2006-10-25
AU2004313688A1 (en) 2005-07-28
US20100130507A1 (en) 2010-05-27
IL176416A (en) 2013-05-30
CA2551409A1 (en) 2005-07-28
US20090030076A1 (en) 2009-01-29
TWI337994B (en) 2011-03-01
JP3984283B2 (ja) 2007-10-03
KR20080007415A (ko) 2008-01-18
GT200500293A (es) 2007-07-06
NO20063567L (no) 2006-09-07
EP1704141A1 (en) 2006-09-27
CA2551409C (en) 2011-02-22
NZ548271A (en) 2010-01-29
BRPI0418245A (pt) 2007-04-17
OA13356A (en) 2007-04-13
AR098931A2 (es) 2016-06-22
IL176416A0 (en) 2006-10-05
ES2767136T3 (es) 2020-06-16
AR047081A1 (es) 2006-01-04
KR100854838B1 (ko) 2008-08-29
UY28709A1 (es) 2005-08-31
BRPI0418245B8 (pt) 2021-05-25
CR8498A (es) 2006-11-15
US7449469B2 (en) 2008-11-11
HUE027357T2 (en) 2016-09-28
CN100469765C (zh) 2009-03-18
GEP20094780B (en) 2009-09-25
EP3002277B1 (en) 2019-11-06
WO2005068421A8 (en) 2006-02-09
KR100850133B1 (ko) 2008-08-04
EP3002277A1 (en) 2016-04-06

Similar Documents

Publication Publication Date Title
ME02433B (me) Nitrooksiderivati prostaglandina
CY1110882T1 (el) Ανταγωνιστες υποδοχεων ορεξινης υποκατεστημενης διαζεπανης
MA32804B1 (fr) Antagonistes d'isonicotinamide des récepteurs de l'orexine
MA31451B1 (fr) Antagonistes des recepteurs de l'orexine de pyridyl piperidine.
GT200800265A (es) Pirido (3,2-e)piracinas, su uso como inhibidores de fosfadiesterasa 10, y procesos para prepararlas.
ME02402B (me) Derivati azola
MX352434B (es) Formulaciones topicas que tienen biodisponibilidad aumentada.
TW200609231A (en) Mglur1 antagonists as therapeutic agents
PL360495A1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
UA89192C2 (ru) Производные пиролопиримидина и пиролопиридина, замещенные циклической аминогруппой, как антагонисты crf
WO2007025069A3 (en) Diazaspirodecane orexin receptor antagonists
WO2008008551A3 (en) 2-substituted proline bis-amide orexin receptor antagonists
ATE556060T1 (de) Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
HRP20090058A2 (en) Prodrugs of excitatory amino acids
WO2006047237A3 (en) Heterocyclic indanone potentiators of metabotropic glutamate receptors
WO2006020727A3 (en) Methods for treating cns disorders by administration of agents to the nasal cavity
WO2007126934A3 (en) Amidoethylthioether orexin receptor antagonists
BRPI0617673C1 (pt) composições de inibidores de fosfodiesterase do tipo iv
ME02169B (me) Derivat 1,2,4-triazolona
GB2462235A (en) NMDA and MC receptor antagonists exhibiting neuroprotective and memory enhancing activities
WO2004087048A3 (en) Benzamide modulators of metabotropic glutamate receptors
MX2007004976A (es) Antagonistas de receptor m1 y/o m3 en combinacion con otros compuestos activos para tratar trastornos respiratorios.
CR6824A (es) Derivados de arilmetilamina para uso como inhibidores de triptasa
IS7649A (is) Bensamíð- eða fenýlasetamíðafleiður sem nýtast vel sem viðtakabindlar skjaldkirtilshormóns
TW200635906A (en) Substituted triazolone, tetrazolone and imidazolone derivatives for use as a medicine